Triple-negative breast cancer, an aggressive subtype, represents 15% of invasive breast tumors. While patients with triple-negative breast cancer have a relatively poor outcome, with higher relapse rates than for other breast tumor types, these aggressive tumors have more intrinsic responsiveness to neoadjuvant chemotherapy than estrogen receptor-positive tumors. This prospective study investigated whether early changes in 18F-FDG tumor uptake during neoadjuvant chemotherapy (NAC) can predict outcomes.
